GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (STU:48Q) » Definitions » Inventories, Raw Materials & Components

X4 Pharmaceuticals (STU:48Q) Inventories, Raw Materials & Components : €1.37 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals Inventories, Raw Materials & Components?

X4 Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Sep. 2024 was €1.37 Mil.

X4 Pharmaceuticals's quarterly raw materials increased from Mar. 2024 (€0.00 Mil) to Jun. 2024 (€0.57 Mil) and increased from Jun. 2024 (€0.57 Mil) to Sep. 2024 (€1.37 Mil).


X4 Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for X4 Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals Inventories, Raw Materials & Components Chart

X4 Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only - - - - -

X4 Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.57 1.37

X4 Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


X4 Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals Headlines

No Headlines